Autologous hematopoietic stem-cell transplantation for multiple myeloma.

A 59-year-old man is diagnosed with multiple myeloma. It is recommended that he receive induction therapy followed by high-dose melphalan with autologous hematopoietic stem-cell transplantation. Such transplantation improves the remission rate in myeloma by allowing for the administration of a chemotherapy dose that would otherwise be lethal. This approach is considered appropriate only for relatively young patients without major coexisting illnesses.

[1]  S. Rajkumar,et al.  MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. , 2005, Hematology. American Society of Hematology. Education Program.

[2]  B. Björkstrand.  Stem cell transplantation in multiple myeloma , 2005, Hematology.

[3]  B. Barlogie,et al.  Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma , 2008, Cancer.

[4]  B. Djulbegovic,et al.  Early versus deferred treatment for early stage multiple myeloma. , 2003, The Cochrane database of systematic reviews.

[5]  B. Barlogie,et al.  Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989. , 2008, Blood.

[6]  P. L. Bergsagel,et al.  Early genetic events provide the basis for a clinical classification of multiple myeloma. , 2005, Hematology. American Society of Hematology. Education Program.

[7]  F. Dammacco,et al.  Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. , 2002, Blood.

[8]  D. Esseltine,et al.  Safety and efficacy of lenalidomide (Len), bortezomib (Bz), and dexamethasone (Dex) in patients (pts) with newly diagnosed multiple myeloma (MM): A phase I/II study , 2008 .

[9]  D. Kadidlo,et al.  Patient care during infusion of hematopoietic progenitor cells , 2004, Transfusion.

[10]  P. L. Bergsagel,et al.  Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. , 2007, Mayo Clinic proceedings.

[11]  Vincenzo Callea,et al.  Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial , 2006, The Lancet.

[12]  M. Baccarani,et al.  Bortezomib (Velcade®)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) in Preparation for Autologous Stem-Cell (SC) Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM). , 2007 .

[13]  M. Gordon.  Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma , 2009 .

[14]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[15]  R. Foà,et al.  Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Ravaud,et al.  High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. , 1998, Blood.

[17]  R. GonzálezBosch.  Treatment of multiple myeloma , 1959 .

[18]  R. Bataille,et al.  Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation. , 2002, Blood.

[19]  Jason McCoy,et al.  Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Cantor,et al.  In‐hospital complications of autologous hematopoietic stem cell transplantation for lymphoid malignancies , 2008, Cancer.

[21]  Rafael Fonseca,et al.  Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Serge Leyvraz,et al.  Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. , 2006, Blood.

[23]  P. Ravaud,et al.  High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  G. Roodman,et al.  Pathophysiology of myeloma bone disease. , 2007, Best practice & research. Clinical haematology.

[25]  J. Reynolds,et al.  Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  B. Barlogie,et al.  Total therapy with tandem transplants for newly diagnosed multiple myeloma. , 1999, Blood.

[27]  Kenneth C. Anderson,et al.  Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets , 2007, Nature Reviews Cancer.

[28]  P. L. Bergsagel,et al.  Advances in biology of multiple myeloma: clinical applications. , 2004, Blood.

[29]  P. Richardson,et al.  The malignant clone and the bone-marrow environment. , 2007, Best practice & research. Clinical haematology.

[30]  B. Barlogie,et al.  Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2 , 2008, British journal of haematology.

[31]  M. Baccarani,et al.  Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  R. Fonseca,et al.  A Randomized Trial of Lenalidomide Plus High-Dose Dexamethasone (RD) Versus Lenalidomide Plus Low-Dose Dexamethasone (Rd) in Newly Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by the Eastern Cooperative Oncology Group. , 2006 .

[33]  R. Kyle,et al.  Drug therapy: Multiple myeloma , 2004 .

[34]  J. Leonard,et al.  BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. , 2008, Blood.

[35]  B. Barlogie,et al.  Treatment of multiple myeloma. , 2004, Blood.

[36]  M. Beksac,et al.  International uniform response criteria for multiple myeloma , 2006, Leukemia.

[37]  R. Bataille,et al.  Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.

[38]  N. Schmitz,et al.  Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  R. Alon,et al.  The chemokine SDF-1 activates the integrins LFA-1, VLA-4, and VLA-5 on immature human CD34(+) cells: role in transendothelial/stromal migration and engraftment of NOD/SCID mice. , 2000, Blood.

[40]  M. Boccadoro,et al.  Management of multiple myeloma and related-disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO). , 2004, Haematologica.

[41]  P. Moreau,et al.  Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial , 2008 .

[42]  J. S. San Miguel,et al.  High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. , 2005, Blood.

[43]  Zander,et al.  High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. , 1986, Blood.

[44]  T. Mcelwain,et al.  HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA , 1983, The Lancet.

[45]  D. Samson,et al.  Guidelines on the diagnosis and management of multiple myeloma 2005 , 2006, British journal of haematology.

[46]  R. Bataille,et al.  Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myélome. , 2007, Blood.

[47]  M. Ratajczak,et al.  CXCR4–SDF-1 Signalling, Locomotion, Chemotaxis and Adhesion , 2003, Journal of Molecular Histology.

[48]  J. Harousseau.  Role of stem cell transplantation. , 2007, Hematology/oncology clinics of North America.

[49]  K. Fields,et al.  High-Dose Therapy and Stem Cell Transplantation. , 1998, Cancer control : journal of the Moffitt Cancer Center.

[50]  P. L. Bergsagel,et al.  Genetic events in the pathogenesis of multiple myeloma. , 2007, Best practice & research. Clinical haematology.

[51]  F. Mandelli,et al.  Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. , 2004, Blood.

[52]  K. Anderson,et al.  Individualizing treatment of patients with myeloma in the era of novel agents. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Harousseau.  Optimizing peripheral blood progenitor cell autologous transplantation in multiple myeloma. , 1999, Haematologica.

[54]  T. Therneau,et al.  Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. , 2007, The New England journal of medicine.

[55]  P. Sonneveld,et al.  Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. , 2007, Haematologica.

[56]  John Crowley,et al.  Thalidomide and hematopoietic-cell transplantation for multiple myeloma. , 2006, The New England journal of medicine.

[57]  G. Morgan,et al.  High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. , 2003, The New England journal of medicine.

[58]  Laurence Lodé,et al.  Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myélome. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.